Literature DB >> 22357810

Least among equals.

Daniel R Kuritzkes, James G Hakim, Ian Sanne.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22357810      PMCID： PMC3284211          DOI： 10.1093/cid/cir1048

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.

Authors:  Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2005-10-25       Impact factor: 5.226

2.  Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Authors:  Ian Sanne; Herve Mommeja-Marin; John Hinkle; John A Bartlett; Michael M Lederman; Gary Maartens; Charles Wakeford; Audrey Shaw; Joseph Quinn; Robert G Gish; Franck Rousseau
Journal:  J Infect Dis       Date:  2005-02-10       Impact factor: 5.226

3.  Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

Authors:  Joel E Gallant; Allan E Rodriguez; Winkler G Weinberg; Benjamin Young; Daniel S Berger; Michael L Lim; Qiming Liao; Lisa Ross; Judy Johnson; Mark S Shaefer
Journal:  J Infect Dis       Date:  2005-10-25       Impact factor: 5.226

4.  High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Authors:  D Rey; B Hoen; P Chavanet; M P Schmitt; G Hoizey; P Meyer; G Peytavin; B Spire; C Allavena; M Diemer; T May; J L Schmit; M Duong; V Calvez; J M Lang
Journal:  J Antimicrob Chemother       Date:  2008-11-25       Impact factor: 5.790

Review 5.  A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Authors:  Michele W Tang; Phyllis J Kanki; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2012-03       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.